OS Therapies (OSTX) Amortization of Deferred Charges (2023 - 2026)
OS Therapies' (OSTX) quarterly Amortization of Deferred Charges came in at $68972.0 in Q1 2026, up 106.14% YoY from $33458.1 in Q1 2025, and up 106.14% on a QoQ basis from -$1.1 million in Q1 2025.
OS Therapies (OSTX) Amortization of Deferred Charges (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Amortization of Deferred Charges data on file, last reported at $68972.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges rose 106.14% year-over-year to $68972.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$715300.0 (down 159.53% YoY) and the FY2024 annual result came in at $1.4 million, down 46.13% from the prior year.
- Amortization of Deferred Charges rose to $68972.0 in Q1 2026, from -$1.1 million in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $981143.0 in Q3 2023 to a low of -$1.1 million in Q1 2025.
- A 4-year average of $335394.3 and a median of $508654.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2025 — Amortization of Deferred Charges plunged 293.97% — and 2026, when it jumped 106.14%.
- Tracing OSTX's Amortization of Deferred Charges over 4 years: stood at $213235.0 in 2023, then jumped by 58.65% to $338289.0 in 2024, then plunged by 431.83% to -$1.1 million in 2025, then soared by 106.14% to $68972.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at $68972.0 (Q1 2026), -$1.1 million (Q1 2025), and $338289.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | OS Therapies | 19.46 Mn | 19.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68,972.00 |
| Mar 31, 2026 | 68,972.00 |
| Mar 31, 2025 | -1.12 Mn |
| Mar 31, 2025 | -1.12 Mn |
| Sep 30, 2024 | 338,289.00 |
| Sep 30, 2024 | 338,289.00 |
| Jun 30, 2024 | 508,654.00 |
| Jun 30, 2024 | 508,654.00 |
| Mar 31, 2024 | 578,736.00 |
| Mar 31, 2024 | 578,736.00 |
| Dec 31, 2023 | 213,235.00 |
| Dec 31, 2023 | 213,235.00 |
| Sep 30, 2023 | 981,143.00 |
| Sep 30, 2023 | 981,143.00 |
| Jun 30, 2023 | 835,928.00 |
| Jun 30, 2023 | 835,928.00 |
| Mar 31, 2023 | 616,153.00 |
| Mar 31, 2023 | 616,153.00 |